CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Culture Biosciences›
News
Culture Biosciences

Culture Biosciences

Culture Biosciences: Automated bio-reactors for biotech, enhancing product development and market speed.

San Francisco, CA, US🇺🇸
Founded
2016
Accelerator
Y Combinator logoY CombinatorW18
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Latest News About Culture Biosciences

Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth

Culture Biosciences

Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth

Culture Biosciences announced Mike Stapleton's appointment to its board as the company scales its Stratyx hardware platform and Console...

Apr 14, 2026

Culture Biosciences Announces Close of Series C Round to Accelerate Commercial Growth of Stratyx 250 and Console Platform

Culture Biosciences

Culture Biosciences Announces Close of Series C Round to Accelerate Commercial Growth of Stratyx 250 and Console Platform

Culture Biosciences announced the close of a Series C financing to expand Stratyx 250 hardware and its Console software platform.

Dec 16, 2025

Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine Learning

Culture Biosciences

Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine Learning

Xcell Biosciences and Culture Biosciences announced a collaboration combining Xcellbio instrumentation with Culture's cloud-native analysis...

Dec 9, 2025

Culture Biosciences unveils Stratyx 250, the first cloud-integrated, mobile bioreactor for cell culture process development

Culture Biosciences

Culture Biosciences unveils Stratyx 250, the first cloud-integrated, mobile bioreactor for cell culture process development

Culture Biosciences announced Stratyx 250, a mobile cloud-integrated bioreactor combining automation, remote process control, and...

Apr 1, 2025

Culture Biosciences Appoints Chris Williams as Chief Executive Officer

Culture Biosciences

Culture Biosciences Appoints Chris Williams as Chief Executive Officer

Culture Biosciences announced Chris Williams as chief executive officer, effective October 7, 2024, bringing bioprocessing and life-science...

Sep 26, 2024

Culture Biosciences and Google Cloud Announce Collaboration to Revolutionize Bioprocess Development

Culture Biosciences

Culture Biosciences and Google Cloud Announce Collaboration to Revolutionize Bioprocess Development

Gemini AI integration with first upstream cloud-connected bioreactors will allow scientists in R&D bioprocess development to achieve...

Sep 10, 2024